Like most website operators, Optimapharm collects non-personally-identifying information of the sort that web browsers and servers typically make available, such as the browser type, language preference, referring site, and the date and time of each visitor request.
Optimapharm’s purpose in collecting non-personally identifying information is to better understand how Optimapharm’s visitors use its website. From time to time, Optimapharm may release non-personally-identifying information in the aggregate, e.g., by publishing a report on trends in the usage of its website.
Optimapharm discloses potentially personally-identifying and personally-identifying information only to those of its employees, contractors and affiliated organizations that (i) need to know that information in order to process it on Optimapharm’s behalf or to provide services available at Optimapharm’s websites, and (ii) that have agreed not to disclose it to others.
Some of those employees, contractors and affiliated organizations may be located outside of your home country; by using Optimapharm’s websites, you consent to the transfer of such information to them. Optimapharm will not rent or sell potentially personally-identifying and personally-identifying information to anyone.
Other than to its employees, contractors and affiliated organizations, as described above, Optimapharm discloses potentially personally-identifying and personally-identifying information only in response to a subpoena, court order or other governmental request, or when Optimapharm believes in good faith that disclosure is reasonably necessary to protect the property or rights of Optimapharm, third parties or the public at large.
Optimapharm takes all measures reasonably necessary to protect against the unauthorized access, use, alteration or destruction of potentially personally-identifying and personally-identifying information.
If Optimapharm, or substantially all of its assets were acquired, or in the unlikely event that Optimapharm goes out of business or enters bankruptcy, user information would be one of the assets that is transferred or acquired by a third party. You acknowledge that such transfers may occur, and that any acquiror of Optimapharm may continue to use your personal information as set forth in this policy.
I would like to thank you all for the tremendous work done to reach this important milestone for the study in a very challenging and complex global environment. It is the first of many others that we will have to achieve together. Let's keep it up!
Clinical Project Leader, Big Pharma Company
We are very grateful for your hard work and dedication over the past few years. We are delighted to be part of this partnership and look forward to start treating patients in this new therapeutic area soon. We could not have done this without your contribution. We are very excited about the path ahead and can hardly wait to start this study.
Chief Executive Officer, Biotech Company
Corporate team and I would like to sincerely thank all the team members, both global and local, as well as the site staff, who have worked extremely hard to reach this lock! This has been achieved under difficult circumstances, being significantly earlier than planned for this discontinued study and in the middle of the COVID-19 pandemic with lockdowns or curfews in place in many of the countries. A huge thank you to all for your team spirit and commitment to reach this goal!
Clinical Project Lead, Big Pharma Company
Very pleased. Looking forward to getting the country up and running soon.
VP Global Clinical Operations, Medical Device Company